US$ 26.02
glp 1 agonist dementia GLP-1 Medications Associated with Reduced Likelihood of Compared to Other Diabetic Meds Advances in Clinical and Experimental
Description
Note: Prices can vary depending on the pharmacy, location, and dosage

So what makes an alternative "close" to tirzepatide

Moreover, the results of cardiovascular outcome trials in persons with T2D given GLP-1RA demonstrating reduced stroke, myocardial infarction, and cardiovascular death 35 along with the emerging evidence demonstrating positive effects of GLP-1RAs 36,37 on kidney outcomes adds further impetus that these drugs have pleiotropic benefits

The gastrointestinal side effect profile is consistent with other GLP-1 based therapies
